{"filings":[{"id":2191639,"accession_number":"0001731122-26-001042","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-08-11T21:00:32+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anavex files proxy for Sep 24 meeting, adds two independent directors amid PVG proxy fight","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 annual meeting set for Sep 24, 2026; record date Jul 31, 2026; PVG owns 0.35% of shares.","Board nominates Gautam Patel and Dr. Adrian Senderowicz as new independent directors; half of board refreshed.","Interim CEO Dr. Terrie Kellmeyer leading; blarcamesine advanced in Alzheimer's, Rett, Fragile X with FDA talks.","Anavex urges votes for six WHITE card nominees; cites PVG slate lacks FDA/drug development expertise.","Nasdaq delinquency notice for late Q1 10-Q received May 20, 2026; listing unaffected, compliance plan filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2006917,"accession_number":"0001731122-26-001000","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-08-03T12:26:23+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anavex Life Sciences Announces Board Refresh, Nominates Two New Independent Directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nominates Gautam Patel and Dr. Adrian Senderowicz as new independent director candidates for 2026 Annual Meeting.","Current board members Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Dr. Claus van der Velden also stand for reelection.","Urges stockholders to reject PVG Asset Management and Patrick Adams' attempt to replace entire board; PVG owns only 0.35% of shares.","Former CEO Christopher Missling terminated for cause and not renominated; Dr. Terrie Kellmeyer appointed interim CEO.","Company focuses on blarcamesine for Alzheimer's, Rett syndrome, Fragile X; strong cash runway, no long-term debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1950437,"accession_number":"0001731122-26-000988","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-07-30T12:15:52+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anavex reports preliminary Q2 FY2026 net loss of $5.3M; cash $127.4M; focuses on FDA for Alzheimer's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary net loss $5.3M ($0.06/share) vs $11.2M ($0.13/share) in Q2 2025; R&D expenses down to $4.2M from $9.9M.","Cash and equivalents $127.4M as of March 31, 2026, up from $102.6M at Sept 30, 2025; expected to fund operations into mid-to-late FY2028.","Opened IND for early Alzheimer's disease with FDA in March 2026; ADME study expected Q3 2026, DDI study underway.","Aligned with FDA on Phase 3 Rett syndrome protocol for adults; plans to discuss adding pediatric patients.","Submitted plan to regain Nasdaq compliance on July 20, 2026 (Listing Rule 5250(c)(1))."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1730996,"accession_number":"0001731122-26-000957","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-07-20T12:59:34+00:00","items":["8.01"],"status":"ready","headline":"Anavex submits Nasdaq compliance plan to regain listing after late Q1 filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted compliance plan on July 20, 2026 to Nasdaq Staff regarding late Form 10-Q for March 31, 2026.","Plan addresses non-compliance with Nasdaq Listing Rule 5250(c)(1) for timely periodic reports.","Nasdaq Staff reviewing plan; if accepted, extension may be granted; if not, hearing available.","No immediate effect on listing; common stock continues trading on Nasdaq under symbol AVXL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1285556,"accession_number":"0001731122-26-000889","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-06-26T10:15:57+00:00","items":["8.01"],"status":"ready","headline":"Anavex sets 2026 annual meeting for September 24; record date July 31, stockholder proposal deadline July 10","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting date set for September 24, 2026; record date for voting is July 31, 2026.","Meeting is more than 30 days after 2025 annual meeting anniversary, triggering revised stockholder proposal deadlines.","Rule 14a-8 proposals and director nominations must be received by July 10, 2026.","Proposals should be sent to Anavex's principal executive offices at 630 5th Ave, 20th Fl, New York, NY 10111."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":591796,"accession_number":"0001731122-26-000781","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-05-22T12:15:26+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Anavex receives Nasdaq delinquency notice for late 10-Q filing; deadline July 20, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice received May 20, 2026 due to late Form 10-Q for quarter ended March 31, 2026.","Company must submit a compliance plan by July 20, 2026 to regain listing compliance.","If plan is accepted, Nasdaq may grant an exception until November 16, 2026 to file.","No immediate effect on AVXL listing; stock continues trading on Nasdaq Global Select.","Anavex states it is working to complete and file the 10-Q and submit the compliance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":471116,"accession_number":"0001731122-26-000744","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-05-15T20:15:25+00:00","items":["5.02"],"status":"ready","headline":"Anavex COO Felix Lauscher departs May 11 amid reorganization after interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Felix Lauscher, COO since March 1, 2026, left Anavex on May 11, 2026.","Departure part of broader reorganization after appointing Dr. Terrie Kellmeyer as Interim CEO.","Lauscher had $264K annual base salary; received prorated pay for service period.","Of 50,000 stock options granted, 45,833 forfeited; 4,167 vested at $4.69/share exercisable until Aug 9, 2026.","Offered two weeks' additional compensation at base salary in exchange for general release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92033,"accession_number":"0001731122-26-000678","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anavex terminates CEO Christopher Missling for cause; appoints Terrie Kellmeyer as interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Missling terminated as CEO for cause effective April 30, 2026; Board requested his resignation.","Terrie Kellmeyer appointed Interim CEO effective May 4, 2026; former SVP Clinical Development at Anavex.","Kellmeyer's compensation: $500k base salary, 30% bonus, $150k signing bonus, 200k stock options pending.","Company expects to file Form 12b-25 to extend deadline for Q2 2026 10-Q (quarter ended March 31, 2026).","Conference call to discuss Q2 2026 financial results and filing to be scheduled later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102518,"accession_number":"0001731122-26-000482","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anavex withdraws EU marketing application for blarcamesine for early Alzheimer's after CHMP negative feedback","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Withdrew EU marketing authorization application for blarcamesine as add-on therapy for early Alzheimer's disease.","Decision follows CHMP indication it would not issue a positive opinion at this time.","Company will gather additional data and conduct further analyses to address CHMP concerns.","Anavex had submitted application after EMA SME Office encouragement in October 2023.","CEO affirms commitment to advancing oral therapies for early Alzheimer's and continuing regulatory engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102517,"accession_number":"0001731122-26-000305","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Anavex appoints Dr. Axel Paeger to Board of Directors effective Feb 23, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Paeger appointed to fill a vacancy on the board, effective February 23, 2026.","Board determined Paeger is independent under Exchange Act and Nasdaq rules.","Paeger is CEO of AMEOS Group, Europe's leading healthcare provider with 85 hospitals and 19,300 employees.","No arrangements or transactions requiring disclosure under Item 404(a) between Paeger and Anavex.","Paeger brings 30+ years of healthcare leadership; compensation consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102516,"accession_number":"0001731122-26-000193","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anavex reports Q1 FY2026 net loss $5.7M; EU blarcamesine setback, re-examination ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.7M ($0.06 per share) vs. $12.1M ($0.14) in Q1 FY2025; R&D expenses dropped to $4.7M from $10.4M.","Cash & equivalents $131.7M (up from $102.6M); company expects cash runway >3 years.","EU CHMP issued negative opinion for blarcamesine in early Alzheimer's; Anavex requested EMA re-examination (Dec 2025).","FDA Type C meeting in Jan 2026 showed interest; company will submit additional Phase IIb/III data for potential NDA.","Appointed Wolfgang Liedtke as SVP Global Head of Neurology; joined ACCESS-AD initiative."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118784,"accession_number":"0001731122-25-001591","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anavex Life Sciences Reports Fiscal 2025 Q4 Net Loss of $9.8M and CHMP Negative Vote for Blarcamesine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 fiscal 2025 was $9.8M ($0.11 per share), compared to net loss of $11.6M ($0.14) in Q4 fiscal 2024.","Cash and cash equivalents were $102.6M at September 30, 2025, down from $132.2M a year ago; current cash over $120M with >3 year runway.","CHMP of EMA issued a negative trend vote on the Marketing Authorisation Application for blarcamesine; Anavex intends to request re-examination.","Positive topline results from Phase 2 study of ANAVEX3-71 for schizophrenia: safe and well-tolerated, primary safety endpoint met.","Research & development expenses for the quarter were $7.3M, down from $11.6M in the prior year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118783,"accession_number":"0001731122-25-001536","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anavex receives negative CHMP trend vote on blarcamesine MAA; plans re-examination","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP issued negative trend vote on MAA for blarcamesine for early Alzheimer's; formal opinion expected December 2025.","Company intends to request re-examination upon formal adoption, including providing relevant biomarker data.","FDA advised Anavex to request a meeting to discuss Alzheimer's clinical trial results.","No change to ongoing FDA review process; company remains in dialogue with regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135316,"accession_number":"0001731122-25-001033","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Anavex Life Sciences enters $150M at-the-market equity facility with TD Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with TD Securities (USA) LLC for ATM offering of up to $150M in common stock.","Shares sold under shelf registration statement filed July 14, 2025, effective July 23, 2025.","Sales agent commission up to 3.0% of gross proceeds; company not obligated to sell any shares.","Sales may be conducted on Nasdaq or in negotiated transactions; offering can be suspended by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135315,"accession_number":"0001731122-25-000935","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anavex extends CEO Missling's term to 2028 with $800k salary; PFO receives indefinite term and increased severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Christopher Missling's employment term extended through July 5, 2028, with base salary $800,000 and target cash bonus of 20% of salary.","PFO Sandra Boenisch's employment made indefinite; base salary set at CAD $279,840 with 20% target bonus.","Boenisch's severance upon termination without cause increased from 6 to 12 months of base salary.","Both amendments effective July 3, 2025; Missling's annual equity grant remains at Compensation Committee's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152280,"accession_number":"0001731122-25-000878","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Anavex shareholders OK plan amendment to add 4M shares, enforce one-year vesting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2022 Omnibus Incentive Plan increases authorized shares from 10M to 14M.","New awards subject to minimum one-year vesting; exceptions for substitutions, cash awards, 5% pool, change in control, death/disability.","Liberal share recycling prohibited: shares used for exercise price or tax withholding cannot be re-added to plan reserve.","All six director nominees elected (Missling, Ma, van der Velden, Skarpelos, Thomas, Donhauser) with >85% of votes cast.","Ratification of Grant Thornton LLP as independent auditor received 49.6M for vs 1.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204605,"accession_number":"0001731122-24-001160","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Anavex terminates at-the-market equity offering agreement with Cantor Fitzgerald and SVB Securities","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Terminated the Amended and Restated Sales Agreement dated May 1, 2020 effective July 24, 2024.","Agreement allowed sale of common stock (AVXL) at company's discretion through Sales Agents.","No penalties associated with the termination.","Sales Agents were Cantor Fitzgerald & Co. and SVB Securities LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221416,"accession_number":"0001731122-24-001003","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anavex Life Sciences Announces Results of 2024 Annual Meeting of Stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected six directors including Christopher Missling, PhD, with 30,256,642 for and 3,637,351 against, plus 22,413,981 broker non-votes.","Ratified Grant Thornton LLP as independent auditor with 54,408,426 for, 1,275,036 against, and 624,512 abstentions.","Approved non-binding advisory resolution on executive compensation (say-on-pay) with 28,406,111 for, 4,728,255 against.","Shareholder proposal on golden parachutes failed with 18,454,499 against, 13,199,210 for, and 2,240,280 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221415,"accession_number":"0001731122-24-000758","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Anavex Q2 FY2024 net loss $10.5M, cash $139.4M; blarcamesine EMA submission underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.5M ($0.13/share) vs $13.1M loss ($0.17/share) in prior-year quarter.","Cash and equivalents $139.4M at Mar 31, 2024; estimated ~4-year runway at current burn rate.","R&D expenses $9.7M, G&A $2.8M; no revenue as clinical-stage biopharma.","Marketing Authorisation application for blarcamesine (Alzheimer's) submitted to EMA; FDA guidance supports single cognitive endpoint.","First cohort fully enrolled in ANAVEX3-71 Phase 2 schizophrenia trial; Phase 2b/3 Alzheimer's data to be published."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293345,"accession_number":"0001731122-23-001007","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anavex shareholders elect all six directors, ratify Grant Thornton LLP at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["65% of outstanding shares (52.1M) represented at May 23, 2023 meeting.","All six director nominees elected, including CEO Christopher Missling (24.8M for, 1.9M withheld).","Ratification of Grant Thornton LLP as auditor passed with 51.1M for, 0.7M against, 0.3M abstain.","No broker non-votes on auditor ratification; all directors had ~25.3M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293344,"accession_number":"0001731122-23-000651","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Anavex amends bylaws to require independent Board Chair, CEO cannot hold the role","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board of Directors adopted amended bylaws on April 11, 2023, effective immediately.","Chairman of the Board must be an independent director and cannot be held by the CEO.","Amended and Restated Bylaws filed as Exhibit 3.1 to the 8-K.","Previous bylaws allowed CEO to serve as Chairman; separation enhances governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313977,"accession_number":"0001731122-23-000348","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Anavex confirms no exposure to Silicon Valley Bank deposits or accounts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds no deposits, securities, or accounts at Silicon Valley Bank.","Disclosure filed as Regulation FD in response to SVB collapse.","Removes investor uncertainty regarding SVB-related financial risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313976,"accession_number":"0001731122-23-000156","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anavex files prospectus supplement for shares issuable under Lincoln Park purchase agreement","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Entered Purchase Agreement with Lincoln Park Capital Fund on Feb 3, 2023.","Prospectus supplement filed Feb 7 to register shares of common stock under the agreement.","Legal opinion from Snell & Wilmer issued regarding the shares.","Potential future share sales could dilute existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332425,"accession_number":"0001731122-22-002078","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anavex Life Sciences announces positive Phase 2b/3 trial results for ANAVEX2-73 in Alzheimer's disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial met primary endpoints ADAS-Cog and ADCS-ADL with statistically significant results (p=0.033 and p=0.0255).","Key secondary endpoint CDR-SB also met (p=0.040), showing 27% reduction in clinical decline.","Patients treated with ANAVEX2-73 were 84% more likely to have improved cognition vs placebo (Odds Ratio=1.84).","ANAVEX2-73 demonstrated 45% reduction in cognitive decline measured by ADAS-Cog compared to placebo.","Company plans to meet with regulatory authorities to discuss next steps for approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366987,"accession_number":"0001731122-22-001011","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Anavex shareholders approve 2022 Omnibus Incentive Plan and re-elect all six directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with 29.3M-26.9M votes for; broker non-votes 22.8M each.","Shareholders ratified Grant Thornton as auditor: 52.4M for, 452.9K against, 532.8K abstain.","2022 Omnibus Incentive Plan approved: 19.2M for, 10.7M against, 687.5K abstain, 22.8M broker non-votes.","Total 53.4M shares voted, representing 69% of outstanding common stock as of record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366986,"accession_number":"0001731122-22-000700","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Anavex extends CEO Missling's contract through July 2025; grants 500K options tied to clinical milestones","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Christopher Missling's employment agreement extended to July 5, 2025.","Base salary increased to $700,000 annually effective July 5, 2022, with target bonus of 20%.","Grant of 500,000 options vesting upon completion of three clinical trial milestones (Alzheimer’s Phase 2b/3, Parkinson’s trial initiation, Fragile X Phase 2/3 initiation).","Options exercise price equals closing price on grant date; accelerated vesting upon change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386376,"accession_number":"0001731122-22-000366","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["4.01","5.02","7.01","9.01"],"status":"ready","headline":"Anavex Life Sciences changes auditor from BDO to Grant Thornton LLP; no disagreements reported","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed BDO as independent auditor on March 1, 2022; no adverse opinions or disagreements in prior two fiscal years.","Engaged Grant Thornton as new independent auditor for FY ending Sep 30, 2022 after competitive process by Audit Committee.","Entered Amendment No.2 to employment agreement with Principal Financial Officer Sandra Boenisch, effective March 1, 2022, increasing annual base salary to $240,000 CAD.","Press release issued March 4, 2022 announcing the auditor change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386375,"accession_number":"0001731122-22-000164","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2022-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anavex clarifies AVATAR Phase 3 trial endpoints; plans FDA meeting for Rett syndrome approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anavex clarifies that the January 2022 clinicaltrials.gov update was not real-time and does not reflect late endpoint/phase changes.","AVATAR Phase 3 endpoints were updated per ICH guidelines and approved by UK MHRA and Australian HREC before the study.","Based on AVATAR Phase 3 and prior Phase 2 success, Anavex plans to meet with FDA to discuss approval pathway for blarcamesine in Rett.","No FDA-approved drugs for Rett syndrome; blarcamesine has Fast Track, Rare Pediatric Disease, and Orphan Drug designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386374,"accession_number":"0001731122-22-000148","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anavex Life Sciences releases data presentation via webcast; details not disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Christopher Missling and CMO Ed Hammond presented data via webcast on February 2, 2022.","Exhibit 99.1 referenced but not included in provided text; content unknown.","No financial or clinical results specified in the 8-K filing.","Investors should review the full presentation for material information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423274,"accession_number":"0001731122-21-001568","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2021-09-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Anavex Life Sciences uplists to Nasdaq Global Select Market, ticker AVXL unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common stock approved for listing on Nasdaq Global Select Market, effective September 27, 2021.","Previously traded on Nasdaq Capital Market; ticker symbol remains AVXL.","Uplisting reflects meeting Nasdaq Global Select Market's higher financial and liquidity requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423273,"accession_number":"0001731122-21-001498","cik":1314052,"company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Anavex presents at H.C. Wainwright conference; no material new information filed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presented corporate deck at H.C. Wainwright 23rd Annual Global Investment Conference on Sep 13, 2021.","CEO Christopher Missling delivered the presentation via webcast.","No financial results, pipeline updates, or guidance disclosed in the 8-K filing.","Exhibit 99.1 investor presentation is furnished but not filed with the SEC.","Filing is a Regulation FD disclosure without substantive operational details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":263187798.81159425,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}